Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19.

Gargouri, Mohamed; Alzwi, Aboubaker; Abobaker, Anis

Gargouri, Mohamed; Alzwi, Aboubaker; Abobaker, Anis.

Gargouri M; Department of Pathology, Benghazi University, Benghazi, Libya.
Alzwi A; 7th of October Hospital, Benghazi, Libya.
Abobaker A; Spire Fylde Coast Hospital, Blackpool, United Kingdom. Electronic address: anis.abobaker@yahoo.com.

Med Hypotheses ; 146: 110380, 2021 01.

Article in English | MEDLINE | ID: covidwho-912501

Subject(s)

COVID-19 Drug Treatment; Cyclin-Dependent Kinases/antagonists & inhibitors; Protein Kinase Inhibitors/therapeutic use; SARS-CoV-2/drug effects; COVID-19/enzymology; Cell Cycle/drug effects; Cell Division/drug effects; Humans; Protein Kinase Inhibitors/pharmacology; SARS-CoV-2/physiology; Virus Replication/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cyclin-Dependent Kinases / Protein Kinase Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Med Hypotheses Year: 2021 Document Type: Article Affiliation country: J.mehy.2020.110380

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google